New oral diabetes drugs may also protect patients' kidney health
In a clinical trial of patients with type 2 diabetes, canagliflozin (a sodium-glucose cotransporter 2 inhibitor) slowed kidney function decline to a greater extent than glimepiride (a sulfonylurea), while having similar blood sugar –lowering effects, report investigators. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 19, 2016 Category: Science Source Type: news
Canagliflozin benefits cohort of type 1 diabetes patients
NEW ORLEANS – Compared with placebo, canagliflozin improved glycemic control and reduced glycemic variability over 18 weeks in adults with type 1 diabetes that had been inadequately controlled with... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - July 11, 2016 Category: Endocrinology Source Type: news
EMA Extends Amputation Investigation to All SGLT2 InhibitorsEMA Extends Amputation Investigation to All SGLT2 Inhibitors
In a revision of its April 2016 notice regarding canagliflozin and amputations, the EMA's Pharmacovigilance Risk Assessment Committee is now investigating all drugs in the class. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - July 8, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
La FDA refuerza las advertencias relacionadas con el riñón para los medicamentos para la diabetes canagliflozina (Invokana, Invokamet) y dapagliflozina (Farxiga, Xigduo XR)
[6-14-2016] La Administración de Alimentos y Medicamentos de EE. UU. (FDA) ha reforzado la advertencia existente acerca del riesgo de lesión renal aguda para los medicamentos para la diabetes tipo 2 canagliflozina (Invokana, Invokamet) y dapagliflozina (Farxiga, Xigduo XR). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 17, 2016 Category: Drugs & Pharmacology Source Type: news
FDA Strengthens Kidney Warnings on J&J, AZ Diabetes Meds
The FDA has revised the warning labels on Johnson & Johnson’s Invokana and AstraZeneca’s Farxiga. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - June 16, 2016 Category: Pharmaceuticals Source Type: news
FDA Strengthens Warnings on Two Diabetes Drugs (FREE)
By Kristin J. Kelley
Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, FASAM
Two drugs used to treat type 2 diabetes — canagliflozin and dapagliflozin — are associated with an increased risk for acute kidney injury, cautions the … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - June 15, 2016 Category: Primary Care Source Type: news
SGLT2 Inhibitor Adds to Weight Loss With Phentermine (CME/CE)
(MedPage Today) -- Canagliflozin may have synergistic effect with standard obesity drug (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 15, 2016 Category: Cardiology Source Type: news
Canagliflozin, Dapagliflozin Warnings Strengthened by FDACanagliflozin, Dapagliflozin Warnings Strengthened by FDA
The FDA has strengthened its drug label warnings about the risk for acute kidney injury in patients taking canagliflozin or dapagliflozin for type 2 diabetes. News Alerts (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - June 15, 2016 Category: Drugs & Pharmacology Tags: Diabetes & Endocrinology News Alert Source Type: news
FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR)
[6-14-2016] The U.S. Food and Drug Administration (FDA) has strengthened the existing warning about the risk of acute kidney injury for the type 2 diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 14, 2016 Category: Drugs & Pharmacology Source Type: news
Canagliflozin Leads to Better A1c Control
(MedPage Today) -- Post-hoc analysis also finds lower risk of hypoglycemia (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 2, 2016 Category: Cardiology Source Type: news
FDA Expands Indication of Invokamet (canagliflozin/metformin HCl) to Include First-Line Treatment of Type 2 Diabetes
RARITAN, N.J., May 24, 2016 – Janssen Pharmaceuticals, Inc. (Janssen), today announced the U.S. Food and Drug Administration (FDA) has approved Invokamet, a fixed-dose combination therapy of INVOKANA® (canagliflozin) and metformin hydrochloride,... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 24, 2016 Category: Drugs & Pharmacology Source Type: news
Canagliflozin/Metformin Combo Approved as First Line for DiabetesCanagliflozin/Metformin Combo Approved as First Line for Diabetes
The fixed-dose combination product of canagliflozin and metformin, known as Invokamet, has been approved for first-line treatment of type 2 diabetes in the US. News Alerts (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - May 24, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Los resultados provisionales de un ensayo clínico indican que hay un riesgo mayor de sufrir amputaciones de pies y piernas, afectando sobre todo los dedos de los pies, con el uso de la medicina para la diabetes canagliflozina (Invokana, Invokamet); la FDA investigará
La Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) está alertando al público sobre los resultados de seguridad preliminares de un ensayo clínico aún en marcha en el que se descubrió un aumento en el número de amputaciones de pies y piernas, afectando sobre todo los dedos de los pies, en pacientes tratados con la medicina para la diabetes canagliflozina (Invokana, Invokamet). No hemos determinado si la canagliflozina aumenta el riesgo de sufrir amputaciones de pies y piernas. Actualmente estamos investigando este nuevo problema de seguridad e informaremos al público ...
Source: FDA Center for Drug Evaluation and Research - What's New - May 24, 2016 Category: Drugs & Pharmacology Source Type: news
FDA Warns About Amputation Risk With CanagliflozinFDA Warns About Amputation Risk With Canagliflozin
The agency is investigating whether the two-fold increase in amputations seen in an ongoing trial is attributable to the drug. News Alerts (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - May 19, 2016 Category: Drugs & Pharmacology Tags: Diabetes & Endocrinology News Alert Source Type: news
